KALAHIGH SIGNALRISK10-K

KALA has undergone a dramatic business transformation with massive share dilution (929M vs 6M shares), substantial doubt about going concern ability, and a complete pivot from pharmaceutical development to AI infrastructure for biotech.

The company appears to have executed a reverse merger or similar transaction given the 144x increase in outstanding shares, while simultaneously facing auditor concerns about its ability to continue operations. The strategic pivot to AI represents a complete abandonment of its core pharmaceutical business, creating significant execution risk and uncertainty about management's ability to successfully operate in an entirely different industry.

Comparing 2026-04-15 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reflect a company in severe distress, with cash declining 85% to just $7.6M and total assets shrinking 83% to $9.5M, while liabilities dropped 94% suggesting major debt restructuring or discharge. Despite massive cost reductions in SG&A (-68%) and R&D (-33%), the company's financial position has deteriorated dramatically. The unusual inventory increase amid overall asset decline and the massive reduction in accounts receivable suggest the company has largely exited its previous commercial operations.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-98.7%
$15.3M→$195K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Liabilities
Balance Sheet
-94.2%
$43.2M→$2.5M

Liabilities reduced 94.2% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-85.3%
$17.0M→$2.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-85.2%
$51.2M→$7.6M

Cash declined 85.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-82.9%
$55.5M→$9.5M

Total assets contracted 82.9% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-82%
$52.8M→$9.5M

Current assets declined 82% — monitor working capital adequacy and short-term liquidity.

SG&A Expense
P&L
-68.4%
$65.0M→$20.6M

SG&A reduced 68.4% — improved cost efficiency or headcount reduction improving operating margins.

Inventory
Balance Sheet
+65.2%
$5.2M→$8.6M

Inventory surged 65.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Stockholders Equity
Balance Sheet
-43.3%
$12.3M→$7.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
-32.7%
$27.3M→$18.4M

R&D spending cut 32.7% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-31
ADDED
There were 929,491,578 shares of common stock, par value $0.001 per share, outstanding as of April 10, 2026.
Our principal risks include the following: The Company s auditor has noted substantial doubt about our ability to continue as a going concern.
We have incurred significant losses from operations and negative cash flows from operations since our inception.
If we were to resume research and development activities with respect to KPI-012, KPI-014 or any other product candidate, such activities would be subject to all of the risks inherent in the development of biologics and other pharmaceutical products, including the risk of clinical trial failure, regulatory rejection, manufacturing challenges, and the absence of adequate financing.
We are shifting our business to focus on developing an AI infrastructure platform for the biotech industry that may present risks to our business.
We may not be successful in driving the global deployment and customer adoption of digital offerings, including AI-enabled software solutions.
We are at an early stage of development of our AI platform business and may be unable to successfully develop, commercialize, or generate revenue from Researgency.
Our Researgency business depends on an exclusive license for the Researgency platform, and the termination, modification, or invalidity of that license could materially harm our business.
Regulatory and legislative developments related to the use of AI could adversely affect our use of such technologies in our products, services, and business.
Data security and privacy risks are heightened in our Researgency business given that our platform may process proprietary biological and clinical data of our customers.
REMOVED
There were 6,452,398 shares of common stock, par value $0.001 per share, outstanding as of March 28, 2025.
and its consolidated subsidiaries, and our board of directors refers to the board of directors of KALA BIO, Inc.
Our principal risks include the following: We have incurred significant losses from operations and negative cash flows from operations since our inception.
As of December 31, 2024, we had an accumulated deficit of $667.9 million.
The milestone consideration we are eligible to receive in connection with the sale of our commercial business to Alcon is subject to various risks and uncertainties.
Our substantial indebtedness may limit cash flow available to invest in the ongoing needs of our business and a failure to comply with the covenants under our loan agreement, such as the requirement that our common stock continue to be listed on The Nasdaq Stock Market, or to avoid the occurrence of specified events of default could result in an acceleration of amounts due .
We are substantially dependent on the success of our product candidate, KPI-012.
If we are unable to successfully complete the clinical development of, and obtain marketing approval for, KPI-012 or any other product candidate we may develop in the future, or experience significant delays in doing so, or if, after obtaining marketing approvals, we fail to successfully commercialize such product candidates, our business will be materially harmed.
If clinical trials of KPI-012 or any other biological product candidate that we develop fail to demonstrate potency, safety and purity to the satisfaction of the U.S.
Food and Drug Administration, or FDA, or other regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →